NeuroPax's Biogel Implant Reverses Early Alzheimer's in 14-Patient Trial

Singapore — NeuroPax, a medtech spin-out from the Agency for Science, Technology and Research (A*STAR), announced Phase I trial results on Monday that have already attracted attention from the Alzheimer's Drug Discovery Foundation: its injectable neuro-restorative biogel implant, codenamed NPX-07, restored measurable cognitive function in 12 of 14 early-stage Alzheimer's patients over a six-month observation window.

The NPX-07 implant is a thermoresponsive biogel loaded with allogeneic neural progenitor cells and a degradable peptide scaffold that self-assembles into a 3D micro-environment supporting neuronal regeneration. Delivered via a minimally invasive intrathecal injection at the lumbar region, the gel crosslinks at body temperature and adheres to existing neural tissue without sutures or mechanical anchors.

Trial participants showed an average 4.7-point improvement on the ADAS-Cog13 cognitive assessment scale — a clinically meaningful reversal compared to the typical 2–3 point annual decline seen in untreated early-stage patients. Crucially, no immune rejection events, infections, or serious adverse events were reported across the 14-subject cohort over the six-month period. MRI imaging at three and six months confirmed graft survival and nascent synaptic connectivity formation in responders.

Dr. Tan Mei Ling, NeuroPax's Chief Medical Officer and lead trial investigator, cautioned that Phase I results require validation in larger cohorts. "Fourteen patients is encouraging but not conclusive," she said. "We are initiating a 120-patient Phase IIa randomized controlled trial in Q1 2028 across sites in Singapore, South Korea, and Australia."

NeuroPax has raised $94 million in Series B funding led by Temasek Holdings, with participation from the Dementia Breakthrough Fund. The company projects a potential commercial launch of NPX-07 by 2031 pending regulatory approval.